17-alpha-Estradiol
Alfatradiol
17-alpha-Estradiol (Alfatradiol) is a longevity & bioregulators research compound. A stereoisomer of estradiol that is essentially non-feminizing — it barely activates the classical estrogen receptors, which is precisely why it's interesting. Topically it inhibits 5-alpha-reductase locally in the scalp. Systemically, in rodents, it extends lifespan in males without the feminizing effects that make estradiol a non-starter.
17-alpha-Estradiol quick facts
| Reported research dose (Oral) | 8mg-12mg (scaled) / topical 0.025-0.1% |
| Route | Topical (hair) / oral in rodent studies |
| Frequency | 1x Daily (topical) |
| Half-life | Varies by route |
| Forms | Oral, Topical |
| Evidence level | Rodent lifespan (ITP); topical human use for hair loss in Europe |
| Other forms available | Topical — dosed differently |
Two completely separate stories under one name. The topical version (alfatradiol) is used for androgenetic alopecia in parts of Europe with modest evidence. The longevity story is rodent-only, male-specific, and the human dose is unknown. Don't conflate them — a topical scalp product tells you nothing about systemic safety.
How 17-alpha-Estradiol works
A stereoisomer of estradiol that is essentially non-feminizing — it barely activates the classical estrogen receptors, which is precisely why it's interesting. Topically it inhibits 5-alpha-reductase locally in the scalp. Systemically, in rodents, it extends lifespan in males without the feminizing effects that make estradiol a non-starter.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get 17-alpha-Estradiol
See vetted vendors for 17-alpha-Estradiol →The evidence for 17-alpha-Estradiol
Graded by what exists behind each claim.
✅ Clinically validated
- No human longevity trials. What exists in humans is old dermatology work — it has been used topically for hair loss in Europe, at doses and routes with no relationship to the longevity use.
📊 Correlative data
- The animal result is unusually strong and unusually specific. The NIA Interventions Testing Program — the most rigorous lifespan program there is, run across three independent sites — found it extended median lifespan in male mice only, with no effect in females.
- Human longevity use is minimal and recent. The sex-specific finding has no human counterpart at all.
🧪 Theoretical / extrapolated
- A non-feminizing stereoisomer of estradiol — it has roughly 1/100th the affinity for the classical nuclear estrogen receptor, so it produces metabolic effects without the feminizing ones that make 17-beta-estradiol unusable in men.
- Proposed to act through membrane-bound estrogen receptors and to reduce hepatic inflammation and improve insulin sensitivity.
- The male-only effect is the most informative fact about it. It suggests the benefit works by shifting male metabolic ageing toward a female-typical pattern — which predicts, correctly, that there is nothing left to gain in females. Very few interventions have a mechanism that explains their own limits this cleanly.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What 17-alpha-Estradiol actually does
17-alpha-estradiol differs from ordinary estradiol at exactly one carbon, and that single stereochemical difference is the whole compound. It is the C17 epimer of 17-beta-estradiol: same formula, same mass, same steroid skeleton, hydroxyl group pointing the other way.
What flipping that hydroxyl does to receptor binding. The 17-beta hydroxyl makes a specific hydrogen bond deep in the ligand-binding pocket of the estrogen receptor, and it is a large part of why estradiol binds as tightly as it does. Inverting it costs most of that affinity — two orders of magnitude by the usual estimates — which is why the compound is described as a non-feminizing estrogen. The important qualifier is non-feminizing, not non-estrogenic. At the doses used it does not produce the classical peripheral estrogenic effects, and it is not inert at estrogen receptors.
The receptor evidence, and it is genetic rather than pharmacological. The metabolic benefits of 17-alpha-estradiol in the liver are partially mediated by ER-beta in male mice Mondal 2023 — and partially is the operative word, because knocking out the receptor blunted the effect without abolishing it. Separately, the systemic metabolic benefits are not exclusively mediated by ER-alpha in glutamatergic or GABAergic neurons Camon 2024, although deleting ER-alpha from GABAergic neurons significantly diminished the effect on body weight. Read those two papers together and the picture is a compound acting at both classical receptors, in more than one tissue, with a substantial component in the brain. That is a considerably more interesting molecule than a weak estrogen.
The central component is the part that reframes it. The GABAergic neuron result Camon 2024 places a meaningful share of the metabolic effect in hypothalamic circuitry rather than in liver or adipose tissue. A compound whose peripheral estrogenic activity is negligible but whose central estrogen-receptor activity is preserved is, functionally, a brain-selective estrogen — and that is the most useful one-sentence description of what 17-alpha-estradiol appears to be.
And the sex specificity, which is not a footnote. The lifespan result is in male mice Harrison 2021, and the liver ER-beta result was partially blocked in female but not male knockouts Mondal 2023. The compound behaves differently in the two sexes at the level of which receptor is required, and that pattern is common enough across geroprotectors to be its own review literature Bartke 2023 Knufinke 2023.
Cell, rodent, human — and where it stops
Step one, the lifespan result, and it is one of the cleanest in the field. 17-alpha-estradiol started late in life extends lifespan in aging UM-HET3 male mice, in the same report in which nicotinamide riboside and three other drugs did not affect lifespan in either sex Harrison 2021. Three features make that unusually strong: UM-HET3 mice are genetically heterogeneous rather than an inbred strain, the program tests compounds at multiple independent sites, and the same paper reports the drugs that failed. A study that names its negatives is a study whose positives mean something.
Step two, the mechanism, dissected by genetics. Hepatic metabolic benefits are partially ER-beta-dependent in male mice Mondal 2023; systemic benefits are not exclusively ER-alpha-dependent in the neuronal populations tested, with GABAergic ER-alpha carrying a significant share of the body-weight effect Camon 2024. This is real mechanistic work with conditional knockouts, not a correlational story.
Step three, the sex-specificity literature, which is the obstacle stated as a field. Responses to many anti-aging interventions are sexually dimorphic Bartke 2023, and a systematic review of sex differences in pharmacological interventions on lifespan and healthspan outcomes exists precisely because the pattern is general Knufinke 2023. For this compound the practical consequence is blunt: the lifespan evidence is in males, and a woman extrapolating from it is extrapolating from a result that was not observed in her sex.
Step four, the human use that exists, stated with its citation problem. Topical 17-alpha-estradiol — alfatradiol — is marketed in parts of Europe for androgenetic alopecia, on the rationale of local 5-alpha-reductase inhibition and increased aromatase activity in the follicle. This page could not resolve a primary trial report for that indication through NCBI when it was written, and so states the use without citing one; the site's rule is that a reference is a paper somebody actually opened, and an invented citation would be far worse than saying so.
Where the chain breaks. (1) The lifespan and mechanistic evidence is entirely rodent Harrison 2021 Mondal 2023 Camon 2024. (2) It is male-specific in the lifespan endpoint. (3) There is no human systemic trial with any aging or metabolic endpoint. (4) Mouse doses in the ITP are expressed per kilogram of diet and translating them to a human oral dose is not a multiplication anybody should do casually, particularly for a compound whose margin between non-feminizing and feminizing has never been established in a person.
What would have to be true, and how you would know it was not
Three predictions. The first is the safety boundary, the second is the metabolic signal, and the third is the one that would falsify the non-feminizing claim.
1. The non-feminizing claim is testable and it has a threshold dose. The whole premise is that the compound acts centrally without producing peripheral estrogenic effects. Estradiol measured on a sensitive assay, plus SHBG, at baseline and 12 weeks. SHBG is the sharper instrument here — hepatic SHBG production is exquisitely estrogen-responsive, so a rising SHBG is early evidence of hepatic estrogenic activity even when a person feels nothing. Total testosterone in men in the same draw, since an estrogenic signal suppresses the axis.
2. If the metabolic mechanism transfers, insulin markers move before anything else does. The mouse work is a metabolic story in liver and hypothalamus Mondal 2023 Camon 2024. So: fasting insulin and HbA1c at baseline and 12 weeks, with ALT and AST on a CMP for the hepatic arm. A fall in fasting insulin without a change in estradiol or SHBG would be the result that supports the whole premise, and it is a combination a person can actually measure.
3. The falsification test, and it is the one that stops someone. If SHBG rises substantially, or estradiol rises on a sensitive assay, or breast tenderness appears, the compound is not behaving non-feminizingly at that dose in that person — and since the entire rationale is that it does, that observation invalidates the reason for taking it rather than being a side effect to manage. Nobody has established the dose at which this crosses over in humans, which is exactly why it has to be measured rather than assumed.
What nobody has tested yet
Four experiments nobody has run.
Nobody has established the human non-feminizing dose range. The compound's identity depends on there being a window where central estrogen-receptor effects occur without peripheral ones. That window has been characterized in mice and never in a person. A dose-ranging study with sensitive estradiol, SHBG and gonadotropins as endpoints is a small, cheap, obvious trial and it does not exist.
Nobody has explained the male specificity mechanistically. The lifespan effect is in males Harrison 2021 and the receptor dependence differs by sex in the liver Mondal 2023. Sexual dimorphism in geroprotector response is a recognized pattern Bartke 2023 Knufinke 2023 without a mechanism, and 17-alpha-estradiol is the best-defined case in which to find one.
Nobody has tested whether the central effect can be separated from the peripheral one by design. If a substantial share of the benefit is GABAergic ER-alpha in the hypothalamus Camon 2024, then a compound engineered for central exposure would be a better drug than the epimer. Nobody has attempted it, and the mouse data now says exactly where to aim.
Nobody has run a human trial of any kind with a systemic endpoint. Not metabolic, not aging, not safety. The topical hair-loss use is a different route and a different exposure altogether. The gap between one of the most robust rodent lifespan results in existence and zero human systemic data is the single most notable thing about this compound.
17-alpha-Estradiol — its own safety story, not its class's
17-alpha-estradiol has no approved systemic indication and no human systemic trial. The class block above assumes a body of human experience that does not exist here.
The central risk is that non-feminizing is a dose-dependent property, not a chemical one. The compound binds estrogen receptors with reduced affinity, and the mouse work shows genuine receptor-dependent effects at both ER-alpha and ER-beta Mondal 2023 Camon 2024. Reduced affinity can always be overcome by concentration. No human dose-ranging study has established where that crossover lies, so a person taking an unstudied systemic dose is testing the boundary rather than staying inside it.
The consequences of crossing it are the consequences of estrogen in a male body: gynecomastia, suppression of the gonadal axis with falling testosterone, changes in mood and libido, and the class question of thromboembolic risk that attaches to estrogenic exposure generally. Gynecomastia in particular is the one that does not reliably reverse once glandular tissue has developed.
The sex asymmetry is a safety statement, not only an efficacy one. The lifespan benefit is male-specific Harrison 2021; the receptor dependence differs by sex Mondal 2023; sexual dimorphism in these responses is a documented pattern Bartke 2023 Knufinke 2023. A woman taking this compound is exposed to an estrogen with no demonstrated benefit in her sex, which changes the calculation entirely.
Hormone-sensitive disease is the obvious contraindication. Any estrogen-receptor ligand, however weak, is the wrong compound in the presence of a hormone-receptor-positive malignancy or a personal history of one.
The topical route is a different exposure and is not covered by any of the above. A scalp application delivers a fraction of a systemic dose to a local target, and the systemic risks discussed here scale with systemic exposure.
What this page will not do. Convert a mouse dose to a human one, or repeat non-feminizing as though it were a guarantee. It is one of the most interesting rodent longevity results in existence Harrison 2021, and there is no human systemic evidence of any kind.
Sources read for this page
- Mondal SA, et al. Metabolic benefits of 17alpha-estradiol in liver are partially mediated by ERbeta in male mice. Scientific Reports 2023 · PMID 37330610
- Camon C, et al. Systemic metabolic benefits of 17alpha-estradiol are not exclusively mediated by ERalpha in glutamatergic or GABAergic neurons. GeroScience 2024 · PMID 38776045
- Knufinke M, et al. Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review. Frontiers in Aging 2023 · PMID 37305228
- Bartke A. Responses to Many Anti-Aging Interventions Are Sexually Dimorphic. World Journal of Men's Health 2023 · PMID 37118966
17-alpha-Estradiol — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- The stereochemistry is the entire molecule. Flipping the hydroxyl at C17 costs it roughly two orders of magnitude of estrogenic activity at the classical receptors — it still binds ER-alpha and ER-beta, just weakly. 'Non-feminizing' is a statement about potency, not about a different receptor, and a potency margin is a thing that can be overwhelmed by exposure.
- That distinction decides the whole safety picture. On the scalp, at the exposure a topical solution produces, there is no reason to expect systemic estrogenic effects and none have been a feature of its licensed use. Taken systemically for the longevity claim, there is no reason to assume the same margin holds — and that is a different compound in the only sense that matters, which is dose and route.
- Locally it inhibits 5-alpha-reductase in the follicle, which puts it in the same mechanistic family as finasteride at the scalp without the systemic DHT suppression.
What has actually been reported
- This one has a licensed human record, and it is topical. As an alcoholic scalp solution it is an approved medicine for pattern hair loss in Germany and several Latin American countries, with published trials including in female pattern hair loss. Local irritation is the common complaint and much of it is attributed to the alcohol vehicle rather than the drug; systemic hormonal effects have not been a feature of topical use.
- The efficacy finding from that literature is worth stating plainly rather than selling around: it slowed or stabilized loss rather than increasing hair density or thickness.
- There is no human safety data for systemic use. The rodent lifespan work is the reason anyone in longevity circles has heard of it, and the licensed product is a scalp solution. Those are two different exposures and only one of them has been studied in people.
How to reduce the risk
Same mechanism as the prediction.
- Keep the route matched to the evidence you are citing. The hair evidence is topical and the lifespan evidence is oral, in rodents. Using one to justify the other is the single most common error made with this molecule.
- Photograph the scalp under the same light before starting and at intervals. The documented outcome is 'lost less', which you cannot detect from memory.
- If you take it systemically anyway, treat it as an experiment with a hormone panel attached and a date on which you decide.
What it does to your bloodwork
A fact about the assay.
- For scalp use there is no blood marker to follow. The measurement is photographic — standardized photos before starting, because the documented effect is stabilization and stabilization is invisible without a baseline.
- If it is being taken systemically, estradiol, testosterone and LH/FSH are the markers that would show whether the non-feminizing margin is holding. Note that routine estradiol immunoassays are not designed to tell the two stereoisomers apart, so a result on one is harder to interpret than it looks — ask the lab what method it uses.
What it overlaps with
- On the scalp it is blocking the same enzyme as finasteride and dutasteride. Running them together is two blocks on one step, not a second mechanism.
- Minoxidil is the genuinely additive partner — an unrelated mechanism, which is why it is the pairing that gets studied.
Don't run this if
- Pregnancy, breastfeeding or trying to conceive — it is an estrogen-receptor ligand and there is no data.
- Hormone-sensitive malignancy. Weak is not zero, and there is no human dose-response to reason from.
- Under 18 — no data exists.
The honest unknown
- Whether the rodent result means anything for a human male. The lifespan and late-life function benefits in mice are male-specific and are lost in castrated males, so the effect depends on the gonadal hormone environment it is acting in rather than working independently of it. Nobody has reproduced any of that in a person. Unproven is not ineffective — but the unproven part here is the species, the sex-specificity and the route all at once.
- Whether repeated scalp application produces systemic exposure worth caring about over years. It has not been characterized.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
17-alpha-Estradiol — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What 17-alpha-Estradiol moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — 17-alpha-Estradiol in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside 17-alpha-Estradiol
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
17-alpha-Estradiol — frequently asked questions
What is 17-alpha-Estradiol?
17-alpha-Estradiol (Alfatradiol) is a longevity & bioregulators research compound. A stereoisomer of estradiol that is essentially non-feminizing — it barely activates the classical estrogen receptors, which is precisely why it's interesting. Topically it inhibits 5-alpha-reductase locally in the scalp. Systemically, in rodents, it extends lifespan in males without the feminizing effects that make estradiol a non-starter.
Is the full 17-alpha-Estradiol protocol on this page?
The reported research dose is on this page, along with how 17-alpha-Estradiol works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of 17-alpha-Estradiol?
17-alpha-Estradiol has an approximate half-life of Varies by route, which is part of what determines how often it's dosed.
What forms does 17-alpha-Estradiol come in?
17-alpha-Estradiol is available as: Oral, Topical.
What's the evidence behind 17-alpha-Estradiol?
Current evidence level: Rodent lifespan (ITP); topical human use for hair loss in Europe. 17-alpha-Estradiol is offered for research purposes only and is not an approved medicine.
What 17-alpha-Estradiol is used for
17-alpha-Estradiol appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.